GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRDF · Jun 30, 2026

Cardiff Oncology, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-344545General Corporate

Operating cash generation13thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-11312.50% · OPTIONAL · VALID

Revenue growth33thOwn-history percentile · N=12

Evidence method

Yoy · gp.fundamentals.revenue

-14.05% · CORE · VALID

Operating margin63thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.operating_margin

-9245.19% · CORE · VALID

SBC intensity31thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

884.62% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible

Jun 30, 20230/5 normalizedLevel 3 Sep 30, 20230/5 normalizedLevel 3 Dec 31, 20230/5 normalizedLevel 3 Mar 31, 20240/5 normalizedLevel 3 Jun 30, 20244/5 normalizedLevel 3 Sep 30, 20244/5 normalizedLevel 3 Dec 31, 20244/5 normalizedLevel 3 Mar 31, 20253/4 normalizedLevel 3 Jun 30, 20254/4 normalizedLevel 3 Sep 30, 20255/5 normalizedLevel 3 Dec 31, 20255/5 normalizedLevel 3 Mar 31, 20264/4 normalizedLevel 3 Jun 30, 20264/4 normalizedLevel 4

Period transition

What moved in the state?

Cash Generation Increased

Previous: -29970.73%
Current: -11312.50%
Delta: 18658.23%

Growth Increased

Previous: -62.39%
Current: -14.05%
Delta: 48.34%

Profitability Increased

Previous: -31341.46%
Current: -9245.19%
Delta: 22096.27%

Sbc Intensity Decreased

Previous: 4048.78%
Current: 884.62%
Delta: -3164.17%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Sep 30, 2025

Similarity: 79%
Compared: 4 dimensions
Coverage: 100%

Growth 22.2 · Profitability 16.3 · Sbc Intensity 30.3 · Cash Generation 2.9

Sep 30, 2024

Similarity: 71%
Compared: 3 dimensions
Coverage: 75%

Profitability 26.4 · Sbc Intensity 2.1 · Cash Generation 43.1

Mar 31, 2025

Similarity: 57%
Compared: 3 dimensions
Coverage: 75%

Profitability 53.4 · Sbc Intensity 50.6 · Cash Generation 12.5

Mar 31, 2026

Similarity: 50%
Compared: 4 dimensions
Coverage: 100%

Growth 33.3 · Profitability 62.5 · Sbc Intensity 68.8 · Cash Generation 12.5

Research Graph

Related governed research

Analogous To · CRDF state analogue 4 →Compared To · Biological Products, (No Diagnostic Substances) peers →Analogous To · CRDF state analogue 3 →Analogous To · CRDF state analogue 2 →Analogous To · CRDF state analogue 1 →Has State · Cardiff Oncology, Inc. →Transitioned To · CRDF Fundamental State →Transitioned To · CRDF CASH_GENERATION_INCREASED →Transitioned To · CRDF GROWTH_INCREASED →Transitioned To · CRDF PROFITABILITY_INCREASED →Transitioned To · CRDF SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.